Last reviewed · How we verify
CD7 CAR-T cell intravenous infusion
At a glance
| Generic name | CD7 CAR-T cell intravenous infusion |
|---|---|
| Sponsor | Institute of Hematology & Blood Diseases Hospital, China |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of CD7 CAR-T in Newly Diagnosed High-Risk T-LBL/ALL (EARLY_PHASE1)
- A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex) (PHASE2)
- CD7-CAR-T Cells in Pediatric Relapsed/Refractory CD7+ T-ALL/LL (PHASE1, PHASE2)
- A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL (PHASE1)
- CD7 CAR-T Cell Therapy Targeting CD7-positive Relapsed/Refractory T Cell Lymphoma/Acute Leukemia (NA)
- CD7 CAR-T Cell Sequential Allo-HSCT for Non-malignant Blood and Immune System Diseases (EARLY_PHASE1)
- Clinical Study on the Safety and Efficacy of CD7 CAR-T Cell Sequential Allo-HSCT and Kidney Transplantation in the Treatment of SIOD (EARLY_PHASE1)
- Clinical Study on the Safety and Efficacy of CD7 CAR-T Cell in Patients With Relapsed/Refractory Acute Leukemia (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: